Press release
Cancer Biomarkers Market Opportunity for Development in Emerging Nations
Driving factors such as growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements are expected to boost the market over the years. However, unfavorable regulatory and reimbursement scenario is likely to have a negative impact on the growth of the market in the coming years. In addition, the development opportunities in emerging countries are likely to have a positive effect on the growth of the market in the coming years.The global cancer biomarkers market is expected to reach US$ 31,206.00 Mn in 2027 from US$ 12,175.69 in 2018. The market is estimated to grow with a CAGR of 11.1% from 2019-2027.
Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPBT00002663/?openpr-10144
The global cancer biomarker market, based on biomarker type, has been segmented into genetic biomarkers, protein biomarkers, and other cancer biomarkers. The protein biomarkers segment held the largest share of the market in 2018. Moreover, the reagent segment is anticipated to register the highest CAGR in the market during the forecast period.
The leading companies operating in the cancer biomarkers market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Illumina, Inc., Myriad Genetics, Inc., Hologic Inc., Quest Diagnostics Incorporated, bioMérieux S.A., and Creative Diagnostics among others.
FDA approvals & product launches drive the market for cancer biomarkers. Market players are involved in the manufacturing wide range of cancer biomarkers that offer maximum advantages and early diagnosis. For instance, in May 2019, QIAGEN launched its first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer. PIK3CA Kit, the [PB1] first companion diagnostic assay are used in any cancer indication for the detection of activating mutations in the PIK3CA gene. Additionally, it is the first FDA approved test as guiding treatment decisions in breast cancer utilizing plasma specimens as a liquid biopsy. Moreover, In November 2017, Roche launched DISCOVERY [PB2] Teal HRP chromogen detection kit to improve tissue-based cancer research. This newest addition to the collection of modular-based detection kits is used to identify and profile biomarkers and cell populations in the tissue-based study.
The emerging markets like the Asia Pacific are creating better opportunities for significant market players to expand their business. This is a prime reason for market growth in the forecast period. Most of the major players focus on emerging countries such as India, China, and others owing to a large number of cancer patients and growing medical tourism in developing countries. Most of the emerging countries are preferred place for medical tourism. As per the Australian Institute of Health and Welfare, 140,000 new cases of cancer are diagnosed in 2018. Furthermore, according to the Malaysia Healthcare Travel Council, in 2017, Over 1,050,000+ healthcare travelers, visited Malaysia for healthcare purposes. The low cost of surgeries, advanced technologies with less waiting time for procedures in the region is likely to boost the demand for cancer biomarkers.
Buy Now This Report at: https://www.theinsightpartners.com/buy/TIPBT00002663/?openpr-10144
Reason To Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the cancer biomarkers market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global cancer biomarkers market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Biomarkers Market Opportunity for Development in Emerging Nations here
News-ID: 2044154 • Views: …
More Releases from The Insight Partners
Insect Pest Control - Obtain PDF Sample Copy
The Insect Pest Control Market size is projected to reach US$ 14.85 billion by 2031 from US$ 21.33 billion in 2024. The market is expected to register a CAGR of 5.4% during 2025-2031. The proactive health measures, combined with heightened consumer awareness about disease prevention, have boosted the demand for both professional pest control services and DIY products. The convergence of public health policies, regulatory vigilance, and increased risk perception…
Denim Fabrics - Obtain PDF Sample Copy
The denim fabrics market size is projected to reach US$ 28.69 billion by 2031 from US$ 22.32 billion in 2024. The market is expected to register a CAGR of 3.8% during 2025-2031. The denim fabrics market is growing steadily owing to changing consumer preferences, fashion trends, and increasing accessibility. Denim has evolved from being a utilitarian fabric to a mainstream fashion item, appreciated for its flexibility, comfort, and ease. With…
Photomedicine Devices and Technologies Market Global Rising Demand & Huge Scope …
A new market study report by The Insight Partners on the Photomedicine Devices and Technologies Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period.
Get PDF Sample…
Genetic Testing Services Market Global Rising Demand & Huge Scope Till 2031
Genetic Testing Services Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
